

## PHARMACY POLICY STATEMENT

### North Carolina Marketplace

<b>DRUG NAME</b>	<b>Rebyota (fecal microbiota, live - jslm)</b>
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Background statement: Rebyota is a fecal microbiota suspension for rectal administration approved by the FDA in 2022 for the prevention of *Clostridioides difficile* infection (CDI) in patients 18 years and older following completion of antibiotic treatment for recurrent CDI. This is the first FDA-approved microbiota-based therapy for prevention of recurrent CDI. Antibiotics including vancomycin and fidaxomicin are effective at treating CDI, however symptoms recur in ~15% of patients. Preceding FDA approval of Rebyota, Fecal Microbiota Transplantation (FMT) from donor stool administered via colonoscopy was used for (D)8(A)24( )64(i)8(n)-14( )64(2

